Niki BioSolutions annual return on equity
2018
2019
2020
2021
2022
2023
2024
2025
Niki BioSolutions Return on Equity (ROE) Growth & History (NIKI)
Niki BioSolutions's return on equity was −6.16% for fiscal 2025.
View full Niki BioSolutions company overviewNiki BioSolutions annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −6.16% | +12.40 pp |
| 2024 | 2024-12-31 | −18.56% | −4.63 pp |
| 2023 | 2023-12-31 | −13.93% | +35.92 pp |
| 2022 | 2022-12-31 | −49.85% | +26.71 pp |
| 2021 | 2021-12-31 | −76.55% | −93.46 pp |
| 2020 | 2020-12-31 | 16.91% | +98.23 pp |
| 2019 | 2019-12-31 | −81.32% | −34.50 pp |
| 2018 | 2018-12-31 | −46.82% | — |
Niki BioSolutions quarterly return on equity
Q4.24
Q3.25
Q4.25
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q4 2025 | 2025-12-31 | −1.35% | +2.85 pp |
| Q3 2025 | 2025-09-30 | −2.69% | — |
| Q4 2024 | 2024-12-31 | −4.20% | — |
Niki BioSolutions return on equity trends
Over the last five fiscal years, Niki BioSolutions's return on equity decreased from 16.91% to −6.16%, a change of −23.07 percentage points. The latest reported quarter, Q4 2025, shows −1.35%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Niki BioSolutions source filings ↗